• linkedin
  • Increase Font
  • Sharebar

    GSK Issues Voluntary Recall

    Nearly 600,000 inhalers are being recalled.

    GlaxoSmithKline is recalling Ventolin (albuterol) inhalers. The recall is voluntary, and only affects the United States, according to an FDA Enforcement Report.

    The recall involves three lots of the Ventolin HFA 200D inhalers (6ZP0003, 6ZP9944 and 6ZP9848) manufactured by GSK in Zebulon, NC, totalling about 593,000 units.

    The company had received complaints about bulging of the outside wrapper, which indicated a leak in the inhaler’s propellant. This defect may cause the inhaler to deliver fewer doses than indicated on the inhaler's dose counter. The recall affects asthma inhalers from hospital, pharmacies, retailers, and wholesalers, but patients are not affected. 

    According to GSK spokesman Juan Carlos Molina, GSK does not anticipate a supply impact to Ventolin Inhalers. 


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available